"It's still a buy," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said when asked whether or he likes Salesforce.com (CRM - Get Report) . Adobe Systems (ADBE - Get Report) is also a buy, he added.
Salesforce.com continues to add big contract after big contract, securing an impressive list of clients. However, Cramer did caution that investors might get a better buying opportunity, as shares were as low at $53 just one month ago.
Whether buying now or waiting for a better entry, investors should "be ready" for the potential of such a decline, he reasoned.
Next, Cramer looked at the struggling biotech sector, which he covered in greater, broad detail late last week. Cramer said he and Research Director Jack Mohr decided to sell Eli Lilly (LLY - Get Report) from the Action Alerts PLUS portfolio because its Alzheimer treatment didn't pan out quite as well as hoped.
And while he likes Bristol-Myers Squibb (BMY - Get Report) and Allergan (AGN - Get Report) -- the latter of which is an AAP holding and has been "very weak" -- the whole industry will likely remain under pressure for the time being.
"Take your time," he suggested, adding that other health care stocks, like Boston Scientific (BSX - Get Report) and Edward Lifesciences (EW - Get Report) , the latter of which is soaring on Monday, are still doing well.
First Solar has a big analyst meeting this week, and Deutsche Bank analysts suggested that expectations may be too high. If that is indeed the case and the stock pulls back, that may be a good buying opportunity, he said.
Finally, Cramer looked at FireEye (FEYE - Get Report) . When there are noteworthy cyberattacks, cybersecurity stocks tends to move higher. However, in Cramer's eyes, Palo Alto Networks (PANW - Get Report) "is the play," followed by CyberArk Software (CYBR - Get Report) .
These stocks have a high valuation and have struggled as of late though, Cramer concluded.